Avatrombopag for persistent and chronic immune thrombocytopenia in children: A post hoc analysis of clinical characteristics of response from a phase 3b clinical trial
Authors:
- Rachael F. GraceRGRachael F. Grace
- Göksel LeblebisatanGLGöksel Leblebisatan
- Yesim AydinokYAYesim Aydinok
- Sule UnalSUSule Unal
- Amanda B. GrimesAGAmanda B. Grimes
- Michele P. LambertMLMichele P. Lambert
- Brian D. JamiesonBJBrian D. Jamieson
- Faizan SattarFSFaizan Sattar
- Scott KolodnySKScott Kolodny
- Michael VredenburgMVMichael Vredenburg
Open Access
- 21 July 2026
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 209 (4) , 1818-1827
Abstract
Summary: Avatrombopag treatment resulted in significantly higher platelet response rates in patients when compared with placebo in a phase 3b study of patients with paediatric immune thrombocytopenia (ITP) (NCT04516967). These post hoc analyses of the 12‐week core phase further assessed the efficacy of avatrombopag, considering the influence of baseline characteristics and protocol‐defined dose adjustments on the achievement and sustainability of response. The cumulative percentage of patients who achieved a platelet response (2 consecutive platelet counts ≥50 × 10 9 /L) by days 15 and 22 was 70.4% and 75.9%, respectively, with avatrombopag (placebo, 0% at both days). Only minor differences were observed by baseline characteristics. Among the 92.6% of patients (50/54) treated with avatrombopag who achieved a clinically meaningful platelet response (platelet count ≥30 × 10 9 /L), the mean percentage of time with response was 62.5%. Protocol‐specified dose holds due to a platelet count >250 × 10 9 /L occurred for 61.1% of patients, which may have impacted the efficacy outcomes. 78.3% of non‐durable responders had ≥1 dose holds prompted by a platelet count of 250–400 × 10 9 /L, a platelet count that would not prompt a dose hold in real‐world clinical practice. Avatrombopag demonstrated a clinically meaningful platelet response across the clinical and demographic subgroups in this heavily pre‐treated and refractory paediatric ITP population.Keywords
Funding Information
- Swedish Orphan Biovitrum
This publication has 15 references indexed in Scilit:
- Real‐World Use of Avatrombopag in Children and Adolescents With Immune ThrombocytopeniaPediatric Blood & Cancer, 2025
- Clinical Use of Eltrombopag and Avatrombopag in Pediatric ITP in China: A Real‐World Multicenter Retrospective Cohort StudyAmerican Journal of Hematology, 2024
- Efficacy and safety of avatrombopag in Chinese children with persistent and chronic primary immune thrombocytopenia: A multicentre observational retrospective study in ChinaBritish Journal of Haematology, 2024
- Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US studyBritish Journal of Haematology, 2022
- Optimal use of thrombopoietin receptor agonists in immune thrombocytopeniaTherapeutic Advances in Hematology, 2019
- Immune Thrombocytopenia - Current Diagnostics and Therapy: Recommendations of a Joint Working Group of DGHO, ÖGHO, SGH, GPOH, and DGTIOncology Research and Treatment, 2018
- Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopeniaBritish Journal of Haematology, 2018
- Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled studyThe Lancet, 2016
- Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trialThe Lancet, 2015
- Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled studyThe Lancet Haematology, 2015